Article

Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: A case series and review of the literature

Wellington Regional Medical Center, Florida, USA.
Cutis; cutaneous medicine for the practitioner (Impact Factor: 0.59). 03/2008; 81(2):179-83.
Source: PubMed

ABSTRACT Melasma is a common hyperpigmentation disorder that typically affects women, though up to 10% of white individuals seeking treatment for melasma are men. Melasma can be a source of embarrassment for men because of its association with women and pregnancy. We performed a case series assessing the use of mequinol 2%/ tretinoin 0.01% topical solution in 5 men with melasma. Four of 5 patients achieved complete clearance of melasma at 12 weeks, and 1 patient showed moderate improvement. Side effects were minimal and consisted of stinging in one patient. All patients maintained results at the 16-week follow-up visit. Mequinol 2%/tretinoin 0.01% topical solution was an effective and well-tolerated treatment of melasma in men. The vehicle resulted in good compliance and minimal adverse effects in patients. This is the first report describing the use of mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men; there are no reports in women.

0 Followers
 · 
104 Views
  • Source
    • "1h-Indene, 1-chloro-2,3- dihydro-is used to produce drug " clidanac " which functions as antiinflammatery analgesic [23]. Mequinol is the key constituent of special cosmetic or medicine applicable to the depigmentation of skin [24]. Benzaldehyde, 3,4,5-trimethoxy- is used as synergist and the pharmaceutical intermediate of antibacterial potentiating agent (TMP). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bamboo is the important resource for the sustainable development of Chinese forestry. The researches on the extracts of bamboo were mainly focused on the leaf, bark, shoot and distillate, however, the components of bamboo root extract is unresolved though it has the effect to cure some intractable diseases. Therefore, pyrolysis-GC/MS technology was used to identify and analyze the top value-added biomedical and bioactive components of benzene/ethanol extract of Moso bamboo root. The extract was pyrolyzed at 750 °C in helium atmosphere, and then the pyrolyzate was analyzed by online-linked GC/MS. Relative content of each component was determined by area normalization. 69 compounds representing 99.14% were identified from 74 peaks, and the main components were as: 1,3-benzodioxole, 5-(2-propenyl)-(6.83%), 1,2-benzenedicarboxylic acid, bis(2-methylpropyl) ester (6.02%), phenol, 2,6-dimethoxy-(5.03%), 4.2.2 propella-2,4,7,9-tetraene (4.82%), benzofuran, 2,3-dihydro-(4.39%), phenol, 2,6-dimethoxy-4-(2-propenyl)-(total 4.24% from 3 peaks), 3',5'-dimethoxyacetophenone (4.05%), benzoic acid, butyl ester (3.48%), benzene, 1,2-dimethoxy-4-(2-propenyl)-(3.02%), mequinol (2.95%), eugenol (2.79%), etc. The result showed that the pyrolyzate of benzene/ethanol extract of Moso bamboo root is rich in biomedical components, and also contains some bioactive components which can be used as top value-added materials of high-grade spice, cosmetic, food, and chemical.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Topical retinoids have been used in the treatment of pigmentary disorders such as melasma, actinic lentigines, and postinflammatory hyperpigmentation. This article evaluates the clinical efficacy and tolerability of retinoid treatment for pigmentary disorders through an evidence-based approach. We searched the MEDLINE and The Cochrane Library databases using the keywords 'retinoid' combined with 'melasma,' 'lentigines,' or 'postinflammatory hyperpigmentation.' For each study, the methodology and outcomes were assessed according to specific criteria. There is fair evidence to support the use of topical tretinoin as a monotherapy in the treatment of melasma as well as in the treatment of lentigines (grade B). Adverse effects of topical retinoids are quite frequent, and include local skin irritation, erythema, and peeling, and their severity is mild to moderate. There is evidence to support the use of topical tretinoin in a fixed, triple-combination therapy (hydroquinone 4%/tretinoin 0.05%/fluocinolone acetonide 0.01%) for the treatment of melasma (grade B). There is poor evidence (grade C) to support the use of combination formulations for the treatment of lentigines, and large, randomized, double-blind, controlled trials are needed to further evaluate their use for this indication. In conclusion, there is evidence to support the use of topical retinoids as monotherapy or in combination with other topical agents in the treatment of pigmentary disorders.
    American Journal of Clinical Dermatology 02/2009; 10(4):251-60. DOI:10.2165/00128071-200910040-00005 · 2.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Melasma is a common hypermelanotic disorder affecting the face that is associated with considerable psychological impacts. The management of melasma is challenging and requires a long-term treatment plan. In addition to avoidance of aggravating factors like oral pills and ultraviolet exposure, topical therapy has remained the mainstay of treatment. Multiple options for topical treatment are available, of which hydroquinone (HQ) is the most commonly prescribed agent. Besides HQ, other topical agents for which varying degrees of evidence for clinical efficacy exist include azelaic acid, kojic acid, retinoids, topical steroids, glycolic acid, mequinol, and arbutin. Topical medications modify various stages of melanogenesis, the most common mode of action being inhibition of the enzyme, tyrosinase. Combination therapy is the preferred mode of treatment for the synergism and reduction of untoward effects. The most popular combination consists of HQ, a topical steroid, and retinoic acid. Prolonged HQ usage may lead to untoward effects like depigmentation and exogenous ochronosis. The search for safer alternatives has given rise to the development of many newer agents, several of them from natural sources. Well-designed controlled clinical trials are needed to clarify their role in the routine management of melasma.
    Indian Journal of Dermatology 03/2009; 54(4):303-9. DOI:10.4103/0019-5154.57602
Show more